JAIPUR: Oncologist Dr Hemant Malhotra was nominated as the president of Immuno-Oncology Society of India (IOSI) at its fourth annual congress being held in the city on Saturday.
Dr Malhotra, who is based in Jaipur and serves as the director of Sri Ram Cancer Centre at Mahatma Gandhi Hospital in the city, said IOSI plays a key role in making progress in immunotherapy, the latest advancement in treatment modalities in cancer patients.
“IOSI is a body of clinicians that has equal participation of lab researchers. It provides a platform for better interaction for making speedy progress in immunotherapy,” said Dr Malhotra, who is also the head of medical oncology at the cancer centre.
In immunotherapy, the latest advancement in cancer treatment is chimeric antigen receptor (CAR) T-cell therapy, he said. “The therapy is quite expensive, costing crores of rupees, and is not available in India. Research on it is in progress in India to make it available in our country,” said Dr Malhotra, adding that the matter is under discussion at the ongoing conference.
The effectiveness of low-dose immunotherapy is also being discussed at the IOSI conference, which will be concluded on Sunday. More than 300 cancer specialists from across the country and 12 international experts are participating in it. Only one of the international experts is attending it in person.
Dr Malhotra, who is based in Jaipur and serves as the director of Sri Ram Cancer Centre at Mahatma Gandhi Hospital in the city, said IOSI plays a key role in making progress in immunotherapy, the latest advancement in treatment modalities in cancer patients.
“IOSI is a body of clinicians that has equal participation of lab researchers. It provides a platform for better interaction for making speedy progress in immunotherapy,” said Dr Malhotra, who is also the head of medical oncology at the cancer centre.
In immunotherapy, the latest advancement in cancer treatment is chimeric antigen receptor (CAR) T-cell therapy, he said. “The therapy is quite expensive, costing crores of rupees, and is not available in India. Research on it is in progress in India to make it available in our country,” said Dr Malhotra, adding that the matter is under discussion at the ongoing conference.
The effectiveness of low-dose immunotherapy is also being discussed at the IOSI conference, which will be concluded on Sunday. More than 300 cancer specialists from across the country and 12 international experts are participating in it. Only one of the international experts is attending it in person.
